



10-14-04

PATENT 1647

ATTORNEY DOCKET NO. 073/US/PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EV 493188580 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[X] If checked, two copies of this correspondence are enclosed.

Date of Deposit: 10-13-2004

Dawn M. Janelle
Signature

Dawn M. Janelle

Printed name of person mailing correspondence

Applicant: DONG, Zheng Xin et al.

Art Unit: 1647

Serial No.: 09/674,597

Examiner: Sandra Wegert

Filed: April 9, 2001

Title: PTH2 RECEPTOR SELECTIVE COMPOUNDS

2ND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

[] under 37 CFR 1.97(b), or

(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)

[X] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(e), as checked below, or

[X] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[] under 37 CFR 1.97(d) together with:

[] a Statement under 37 CFR 1.97(e), as checked below, and

[] a Petition under 37 CFR 1.97(d)(2), and

[] a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

[] Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.

(Filed after payment of issue fee)

[X] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

09674597

10/19/2004 WABDELRI 00000046 500590

180.00 DA

01 FC:1806

- ☒ Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of each reference noted thereon.
- ☐ Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of selected references noted thereon. This application was filed after June 30, 2003 and as such, copies of any United States Patent or Patent Publications are not enclosed.
- ☐ Copies of the reference(s) noted on the enclosed form PTO/1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. [] cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. [].

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstracts.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☐ No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,
BIOMEASURE, INCORPORATED

Dated: Oct 13, 2004

By Pamela C Ball
Pamela C. Ball, Agent for Applicant(s)
Registration No.: 53,963

27 Maple Street
Milford, Massachusetts 01757
Phone: (508)478-0144
Facsimile: (508) 473-3531

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
073/US/PCT/USAPPLICATION NO.
09/674,597INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

OCT 13 2004

APPLICANT
DONG, Zheng Xin et al.FILING DATE
April 9, 2001GROUP/EXAMINER
1647/Sandra Wegert

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DA	CLARK, J. A. et al., "Multiple Regions of Ligand Discrimination Revealed by Analysis of Chimeric Parathyroid Hormone 2 (PTH3) and PTH/PTH-Related Peptide (PTHrP) Receptors," Molecular Endocrinology, 1998, 12(2):193-206.
DB	ARIMURA, A. et al., "Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and its Receptors: Neuroendocrine and Endocrine Interaction," Frontiers in Neuroendocrinology, 1995, 16:53-88.
DC	ARIMURA, A., "Pituitary Adenylate Cyclase Activating Polypeptide (PACAP): discovery and current status of research," Regulatory Peptides, 1992, 37:287-303.
DD	CHRISTOPHE, J., "Type I receptors for PACAP (A Neuropeptide even more important than VIP?)," Biochemica et Biophysica Acta, 1993, 1154:183-189.
DE	USDIN, T. et al., "Identification and Functional Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor," J. Biol. Chemistry, 1995, 15455-15458.

EXAMINER

DATE CONSIDERED